中国实用外科杂志2015，Vol.35Issue(7)：749-752,4.DOI:10.7504/CJPS.ISSN1005-2208.2015.07.15
氟维司群联合曲妥珠单抗对人乳腺癌BT-474细胞株协同作用研究
Research on the effectiveness of fulvestrant combined with trastuzumab on the human breast cancer cell line BT-474
摘要
Abstract
Objective To investigate the effectiveness of fulvestrant combined with trastuzumab on the human breast cancer cell line BT-474.Methods Inhibition of BT-474 cell proliferation at different concentrations of fulvestrant, trastuzumab and the two drugs combined was assessed using the WST-1 assay.Flow cytometry(FCM) was used to detect the cell apoptosis rates by Annexin-V/PI assay. Moreover, the effect fulvestrant and trastuzumab respectively and combinedly have on the proteins p-Akt and p-MAPK was detected by Western blot assay. Results The cell proliferation was increasingly inhibited by fulvestrant, trastuzumab or them combined when each group's drug concentration added, with a CIED50 of 0.466.When fulvestrant and trastuzumab combined, the cell apoptosis rates were distinctly increased(P<0.05).Furthermore, the level of proteins p-Akt and p-MAPK expressed in the cell BT-474 was raised by fulvestrant, but definitively reduced when fulvestrant combined with trastuzumab. Conclusion Fulvestrant synergizes trastuzumab if they combine when acing on the cell line BT-474, maybe because fulvestrant combined with trastuzumab increases the cell proliferation inhibition, promotes the cell apoptosis and restrains fulvestrant from enhancing the proteins p-Akt and p-MAPK expression.关键词
乳腺肿瘤/BT-474/氟维司群/曲妥珠单抗Key words
breast neoplasm/BT-474/fulvestrant/trastuzumab分类
医药卫生引用本文复制引用
陈青,吴克瑾,丁龙龙,陆云姝,柏方..氟维司群联合曲妥珠单抗对人乳腺癌BT-474细胞株协同作用研究[J].中国实用外科杂志,2015,35(7):749-752,4.基金项目
上海市科学技术委员会科研计划项目(No.12JC1406800,No.14411950206) （No.12JC1406800,No.14411950206）
